141 related articles for article (PubMed ID: 9643374)
1. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
Zimmerman DH; Ulrich JT; Wright C; Lloyd JP; Winship MD; Sarin PS
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):741-9. PubMed ID: 9643374
[TBL] [Abstract][Full Text] [Related]
2. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
Fiorentini S; Marsico S; Becker PD; Iaria ML; Bruno R; Guzmán CA; Caruso A
Vaccine; 2008 Aug; 26(36):4758-65. PubMed ID: 18602957
[TBL] [Abstract][Full Text] [Related]
6. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.
Jiang JD; Chu FN; Naylor PH; Kirkley JE; Mandeli J; Wallace JI; Sarin PS; Goldstein AL; Holland JF; Bekesi JG
J Acquir Immune Defic Syndr (1988); 1992; 5(4):382-90. PubMed ID: 1372353
[TBL] [Abstract][Full Text] [Related]
7. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.
Sarin PS; Talmadge JE; Heseltine P; Murcar N; Gendelman HE; Coleman R; Kelsey L; Beckner S; Winship D; Kahn J
Vaccine; 1999 Jan; 17(1):64-71. PubMed ID: 10078609
[TBL] [Abstract][Full Text] [Related]
8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
9. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.
Pisarev VM; Parajuli P; Mosley RL; Sublet J; Kelsey L; Sarin PS; Zimmerman DH; Winship MD; Talmadge JE
Int J Immunopharmacol; 2000 Nov; 22(11):865-76. PubMed ID: 11090695
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
Kahn JO; Stites DP; Scillian J; Murcar N; Stryker R; Volberding PA; Naylor PH; Goldstein AL; Sarin PS; Simmon VF
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1321-5. PubMed ID: 1466950
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
13. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
14. Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine.
Pisarev VM; Parajuli P; Mosley RL; Chavez J; Zimmerman D; Winship D; Talmadge JE
Vaccine; 2002 May; 20(17-18):2358-68. PubMed ID: 12009292
[TBL] [Abstract][Full Text] [Related]
15. Tat-neutralizing antibodies in vaccinated macaques.
Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
[TBL] [Abstract][Full Text] [Related]
16. Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.
Zembe L; Burgers WA; Jaspan HB; Bekker LG; Bredell H; Stevens G; Gilmour J; Cox JH; Fast P; Hayes P; Vardas E; Williamson C; Gray CM
PLoS One; 2011; 6(10):e26096. PubMed ID: 22022524
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
18. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
19. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
20. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
